Liposarcoma: Molecular genetics and therapeutics

Sarcoma

Volumn 2011, Issue , 2011, Pages

  Thomas, David M ^a   Conyers, Rachel ^a   Young, Sophie ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

2 (1H INDAZOL 4 YL) 6 (4 METHANESULFONYL 1 PIPERAZINYLMETHYL) 4 MORPHOLINOTHIENO[3,2 D]PYRIMIDINE; 2 MORPHOLINO 8 PHENYLCHROMONE; 4 DIALLYLAMINOMETHYLENE 1,3,4,7,10,11,12,13,14,15,16,17 DODECAHYDRO 6 HYDROXY 1 METHOXYMETHYL 10,13 DIMETHYL 3,7,17 TRIOXO 2 OXACYCLOPENTA[A]PHENANTHREN 11 YL ACETATE; 6 ACETYL 8 CYCLOPENTYL 5 METHYL 2 [5 (1 PIPERAZINYL) 2 PYRIDINYLAMINO] 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; AT 219; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR; FLAVOPIRIDOL; FORETINIB; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; HIGH MOBILITY GROUP A2 PROTEIN; P 1446A05; P 27600; PROTEIN MDM2; R 547; R 7112; RO 5045337; ROSCOVITINE; SERDEMETAN; TRABECTEDIN; TRANSCAINIDE; UNCLASSIFIED DRUG; ZK 304709;

CANCER CELL CULTURE; CYTOTOXICITY; DRUG POTENCY; GENE AMPLIFICATION; GENE MUTATION; GENETIC TRANSCRIPTION; HUMAN; LIPOSARCOMA; MOLECULAR GENETICS; MYXOSARCOMA; NONHUMAN; PATHOGENESIS; PLEOMORPHIC LIPOSARCOMA; PRIORITY JOURNAL; REVIEW; SARCOMA;

EID: 79952216562     PISSN: 1357714X     EISSN: 13691643     Source Type: Journal    
DOI: 10.1155/2011/483154     Document Type: Review

References (174)

1. N. C. Institute, A Snaphsot of Sarcoma, 2010, http://www.cancer.gov/ cancertopics/types/soft-tissue-sarcoma
2. Mack T. M., Sarcomas and other malignancies of soft tissue, retroperitoneum, peritoneum, pleura, heart, mediastinum, and spleen Cancer 1995 75 1 211 244
3. Jemal A., Siegel R., Ward E., Murray T., Xu J., Smigal C., Thun M. J., Cancer statistics, 2006 CA Cancer Journal for Clinicians 2006 56 2 106 130
4. Henricks W. H., Chu Y. C., Goldblum J. R., Weiss S. W., Dedifferentiated liposarcoma: a clinicopathological analysis of 155 cases with a proposal for an expanded definition of dedifferentiat (Pubitemid 27120195)
5. Linehan D. C., Lewis J. J., Leung D., Brennan M. F., Influence of biologic factors and anatomic site in completely resected liposarcoma Journal of Clinical Oncology 2000 18 8 1637 1643 (Pubitemid 30220541)
6. Lewis J. J., Leung D., Woodruff J. M., Brennan M. F., Retroperitoneal soft-tissue sarcoma: analysis of 500 patients treated and followed at a single institution Annals of Surgery 1998 228 3 355 365 (Pubitemid 30191698)
7. McCormick D., Mentzel T., Beham A., Fletcher C. D. M., Dedifferentiated liposarcoma: clinicopathologic analysis of 32 cases suggesting a better prognostic subgroup among pleomorphic sarcomas American Journal of Surgical Pathology 1994 18 12 1213 1223 (Pubitemid 24362434)
8. Gebhard S., Coindre J.-M., Michels J.-J., Terrier P., Bertrand G., Trassard M., Taylor S., Chteau M.-C., Marqus B., Picot V., Guillou L., Pleomorphic liposarcoma: clinicopathologic, immunohistochemical, and follow-up analysis of 63 cases: a study from the French Federation of Cancer Centers Sarcoma Group American Journal of Surgical Pathology 2002 26 5 601 616 (Pubitemid 34438720)
9. Singer S., Antonescu C. R., Riedel E., Brennan M. F., Pollock R. E., Histologic subtype and margin of resection predict pattern of recurrence and survival for retroperitoneal liposarcoma Annals of Surgery 2003 238 3 358 371 (Pubitemid 38174479)
10. Kindblom L.-G., Lipomatous tumorshow we have reached our present views, what controversies remain and why we still face diagnostic problems: a tribute to Dr Franz Enzinger Advances in Anatomic Pathology 2006 13 6 279 285 (Pubitemid 44673443)
11. Rieker R. J., Weitz J., Lehner B., Egerer G., Mueller A., Kasper B., Schirmacher P., Joos S., Mechtersheimer G., Genomic profiling reveals subsets of dedifferentiated liposarcoma to follow separate molecular pathways Virchows Archiv 2010 456 3 277 285
12. Jones R. L., Fisher C., Al-Muderis O., Judson I. R., Differential sensitivity of liposarcoma subtypes to chemotherapy European Journal of Cancer 2005 41 18 2853 2860 (Pubitemid 41713123)
13. de Vreeze R. S. A., de Jong D., Haas R. L., Stewart F., van Coevorden F., Effectiveness of radiotherapy in myxoid sarcomas is associated with a dense vascular pattern International Journal of Radiation Oncology Biology Physics 2008 72 5 1480 1487
14. Pitson G., Robinson P., Wilke D., Kandel R. A., White L., Griffin A. M., Bell R. S., Catton C. N., Wunder J. S., O'Sullivan B., Radiation response: an additional unique signature of myxoid liposarcoma International Journal of Radiation Oncology Biology Physics 2004 60 2 522 526 (Pubitemid 39233472)
15. de Vreeze R. S. A., de Jong D., Nederlof P. M., Ariaens A., Tielen I. H. G., Frenken L., Haas R. L., van Coevorden F., Added value of molecular biological analysis in diagnosis and clinical management of liposarcoma: a 30-year single-institution experience Annals of Surgical Oncology 2009 14 3 686 693
16. Dei Tos A. P., Doglioni C., Piccinin S., Sciot R., Furlanetto A., Boiocchi M., Dal Cin P., Maestro R., Fletcher C. D. M., Tallini G., Coordinated expression and amplification of the MDM2, CDK4, and HMGI-C genes in atypical lipomatous tumours Journal of Pathology 2000 190 5 531 536 (Pubitemid 30164482)
17. Kraus M. D., Guillou L., Fletcher C. D. M., Well-differentiated inflammatory liposarcoma: an uncommon and easily overlooked variant of a common sarcoma American Journal of Surgical Pathology 1997 21 5 518 527 (Pubitemid 27213065)
18. Argani P., Facchetti F., Inghirami G., Rosai J., Lymphocyte-rich well-differentiated liposarcoma: report of nine cases American Journal of Surgical Pathology 1997 21 8 884 895 (Pubitemid 27402807)
19. Hasegawa T., Seki K., Hasegawa F., Matsuno Y., Shimoda T., Hirose T., Sano T., Hirohashi S., Dedifferentiated liposarcoma of retroperitoneum and mesentery: varied growth patterns and histological gradesa clinicopathologic study of 32 cases Human Pathology 2000 31 6 717 727 (Pubitemid 30445476)
20. Tontonoz P., Singer S., Forman B. M., Sarraf P., Fletcher J. A., Fletcher C. D. M., Brun R. P., Mueller E., Altiok S., Oppenheim H., Evans R. M., Spiegelman B. M., Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor and the retinoid X receptor Proceedings of the National Academy of Sciences of the United States of America 1997 94 1 237 241 (Pubitemid 27027193)
21. Weiss S. W., Rao V. K., Well-differentiated liposarcoma (atypical lipoma) of deep soft tissue of the extremities, retroperitoneum, and miscellaneous sites: a follow-up study of 92 cases with analysis of the incidence of dedifferentiation American Journal of Surgical Pathology 1992 16 11 1051 1058
22. Rosai J., Akerman M., Dal Cin P., Combined morphologic and karyotypic study of 59 atypical lipomatous tumors: evaluation of their relationship and differential diagnosis with other adipose tissue tumors. (A report of the CHAMP Study Group) American Journal of Surgical Pathology 1996 20 10 1182 1189 (Pubitemid 26336841)
23. Pedeutour F., Forus A., Coindre J.-M., Berner J.-M., Nicolo G., Michiels J.-F., Terrier P., Ranchere-Vince D., Collin F., Myklebost O., Turc-Carel C., Structure of the supernumerary ring and giant rod chromosomes in adipose tissue tumors Genes Chromosomes and Cancer 1999 24 1 30 41 (Pubitemid 28544460)
24. Forus A., Weghuis D. O., Smeets D., Fodstad O., Myklebost O., Van Kessel A. G., Comparative genomic hybridization analysis of human sarcomas: I. Occurrence of genomic imbalances and identification of a novel major amplicon at 1q21-q22 in soft tissue sarcomas Genes Chromosomes and Cancer 1995 14 1 8 14
25. Szymanska J., Virolainen M., Tarkkanen M., Wiklund T., Asko-Seljavaara S., Tukiainen E., Elomaa I., Blomqvist C., Knuutila S., Overrepresentation of 1q21-23 and 12q13-21 in lipoma-like liposarcomas but not in benign lipomas: a comparative genomic hybridization study Cancer Genetics and Cytogenetics 1997 99 1 14 18 (Pubitemid 27460870)
26. Mariani O., Brennetot C., Coindre J.-M., Gruel N., Ganem C., Delattre O., Stern M.-H., Aurias A., JUN oncogene amplification and overexpression block adipocytic differentiation in highly aggressive sarcomas Cancer Cell 2007 11 4 361 374 (Pubitemid 46518313)
27. Toledo F., Wahl G. M., Regulating the p53 pathway: in vitro hypotheses, in vivo veritas Nature Reviews Cancer 2006 6 12 909 923 (Pubitemid 44862676)
28. Wade M., Wang Y. V., Wahl G. M., The p53 orchestra: Mdm2 and Mdmx set the tone Trends in Cell Biology 2010 20 5 299 309
29. Mendrysa S. M., McElwee M. K., Michalowski J., O'Leary K. A., Young K. M., Perry M. E., mdm2 is critical for inhibition of p53 during lymphopoiesis and the response to ionizing irradiation Molecular and Cellular Biology 2003 23 2 462 473 (Pubitemid 36050541)
30. Kubbutat M. H. G., Ludwig R. L., Levine A. J., Vousden K. H., Analysis of the degradation function of Mdm2 Cell Growth and Differentiation 1999 10 2 87 92 (Pubitemid 29093921)
31. Momand J., Zambetti G. P., Olson D. C., George D., Levine A. J., The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation Cell 1992 69 7 1237 1245
32. Oliner J. D., Pietenpol J. A., Thiagalingam S., Gyuris J., Kinzler K. W., Vogelstein B., Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53 Nature 1993 362 6423 857 860 (Pubitemid 23132165)
33. Thut C. J., Goodrich J. A., Tjian R., Repression of p53-mediated transcription by MDM2: a dual mechanism Genes and Development 1997 11 15 1974 1986 (Pubitemid 27332984)
34. Haupt Y., Maya R., Kazaz A., Oren M., Mdm2 promotes the rapid degradation of p53 Nature 1997 387 6630 296 299 (Pubitemid 27220766)
35. Kubbutat M. H. G., Jones S. N., Vousden K. H., Regulation of p53 stability by Mdm2 Nature 1997 387 6630 299 303 (Pubitemid 27220767)
36. Hu C.-Q., Hu Y.-Z., Small molecule inhibitors of the p53-MDM2 Current Medicinal Chemistry 2008 15 17 1720 1730
37. Stommel J. M., Wahl G. M., Accelerated MDM2 auto-degradation induced by DNA-damage kinases is required for p53 activation The EMBO Journal 2004 23 7 1547 1556 (Pubitemid 38579515)
38. Brooks C. L., Gu W., p53 ubiquitination: Mdm2 and beyond Molecular Cell 2006 21 3 307 315 (Pubitemid 43163526)
39. Michael D., Oren M., The p53-Mdm2 module and the ubiquitin system Seminars in Cancer Biology 2003 13 1 49 58 (Pubitemid 36269180)
40. Mller C. R., Paulsen E. B., Noordhuis P., Pedeutour F., Ster G., Myklebost O., Potential for treatment of liposarcomas with the MDM2 antagonist Nutlin-3A International Journal of Cancer 2007 121 1 199 205 (Pubitemid 46753868)
41. Pilotti S., Della Torre G., Lavarino C., Di Palma S., Sozzi G., Minoletti F., Rao S., Pasquini G., Azzarelli A., Rilke F., Pierotti M. A., Distinct mdm2/p53 expression in patterns in liposarcoma subgroups: implications for different pathogenetic mechanisms Journal of Pathology 1997 181 1 14 24 (Pubitemid 27099769)
42. Schneider-Stock R., Walter H., Radig K., Rys J., Bosse A., Kuhnen C., Hoang-Vu C., Roessner A., MDM2 amplification and loss of heterozygosity at Rb and p53 genes: no simultaneous alterations in the oncogenesis of liposarcomas Journal of Cancer Research and Clinical Oncology 1998 124 10 532 540 (Pubitemid 28513115)
43. Binh M. B. N., Sastre-Garau X., Guillou L., De Pinieux G., Terrier P., Lagac R., Aurias A., Hostein I., Coindre J. M., MDM2 and CDK4 immunostainings are useful adjuncts in diagnosing well-differentiated and dedifferentiated liposarcoma subtypes: a comparative analysis of 559 soft tissue neoplasms with genetic data American Journal of Surgical Pathology 2005 29 10 1340 1347 (Pubitemid 41368770)
44. Nakayama T., Toguchida J., Wadayama B.-I., Kanoe H., Kotoura Y., Sasaki M. S., MDM2 gene amplification in bone and soft-tissue tumors: association with tumor progression in differentiated adipose-tissue tumors International Journal of Cancer 1995 64 5 342 346
45. Ortega S., Malumbres M., Barbacid M., Cyclin D-dependent kinases, INK4 inhibitors and cancer Biochimica et Biophysica Acta 2002 1602 1 73 87 (Pubitemid 34311901)
46. Italiano A., Bianchini L., Gjernes E., Keslair F., Ranchere-Vince D., Dumollard J.-M., Haudebourg J., Leroux A., Mainguen C., Terrier P., Chibon F., Coindre J.-M., Pedeutour F., Clinical and biological significance of CDK4 amplification in well-differentiated and dedifferentiated liposarcomas Clinical Cancer Research 2009 15 18 5696 5703
47. Harbour J. W., Luo R. X., Dei Santi A., Postigo A. A., Dean D. C., Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1 Cell 1999 98 6 859 869 (Pubitemid 29446902)
48. Day P. J., Cleasby A., Tickle I. J., O'Reilly M., Coyle J. E., Holding F. P., McMenamin R. L., Yon J., Chopra R., Lengauer C., Jhoti H., Crystal structure of human CDK4 in complex with a D-type cyclin Proceedings of the National Academy of Sciences of the United States of America 2009 106 11 4166 4170
49. Dei Tos A. P., Doglioni C., Piccinin S., Maestro R., Mentzel T., Barbareschi M., Boiocchi M., Fletcher C. D. M., Molecular abnormalities of the p53 pathway in dedifferentiated liposarcoma Journal of Pathology 1997 181 1 8 13 (Pubitemid 27099768)
50. Hisaoka M., Tsuji S., Morimitsu Y., Hashimoto H., Shimajiri S., Komiya S., Ushijima M., Detection of TLS/FUS-CHOP fusion transcripts in myxoid and round cell liposarcomas by nested reverse transcription-polymerase chain reaction using archival paraffin-embedded tissues Diagnostic Molecular Pathology 1998 7 2 96 101 (Pubitemid 28443097)
51. Kanoe H., Nakayama T., Murakami H., Hosaka T., Yamamoto H., Nakashima Y., Tsuboyama T., Nakamura T., Sasaki M. S., Toguchida J., Amplification of the CDK4 gene in sarcomas: tumor specificity and relationship with the RB gene mutation Anticancer Research 1998 18 4 A 2317 2321 (Pubitemid 28386514)
52. Italiano A., Bianchini L., Keslair F., Bonnafous S., Cardot-Leccia N., Coindre J.-M., Dumollard J.-M., Hofman P., Leroux A., Mainguen C., Peyrottes I., Ranchere-Vince D., Terrier P., Tran A., Gual P., Pedeutour F., HMGA2 is the partner of MDM2 in well-differentiated and dedifferentiated liposarcomas whereas CDK4 belongs to a distinct inconsistent amplicon International Journal of Cancer 2008 122 10 2233 2241 (Pubitemid 351542325)
53. Sirvent N., Coindre J.-M., Maire G., Hostein I., Keslair F., Guillou L., Ranchere-Vince D., Terrier P., Pedeutour F., Detection of MDM2-CDK4 amplification by fluorescence in situ hybridization in 200 paraffin-embedded tumor samples: utility in diagnosing adipocytic lesions and comparison with immunohistochemistry and real-time PCR American Journal of Surgical Pathology 2007 31 10 1476 1489 (Pubitemid 47482460)
54. Aleixo P. B., Hartmann A. A., Menezes I. C., Meurer R. T., Oliveira A. M., Can MDM2 and CDK4 make the diagnosis of well differentiated/ dedifferentiated liposarcoma? An immunohistochemical study on 129 soft tissue tumours Journal of Clinical Pathology 2009 62 12 1127 1135
55. Arlotta P., Tai A. K.-F., Manfioletti G., Clifford C., Jay G., Ono S. J., Transgenic mice expressing a truncated form of the high mobility group I-C protein develop adiposity and an abnormally high prevalence of lipomas The Journal of Biological Chemistry 2000 275 19 14394 14400 (Pubitemid 30339724)
56. Bustin M., Reeves R., High-mobility-group chromosomal proteins: architectural components that facilitate chromatin function Progress in Nucleic Acid Research and Molecular Biology 1996 54 35 100
57. Meza-Zepeda L. A., Berner J.-M., Henriksen J., South A. P., Pedeutour F., Dahlberg A. B., Godager L. H., Nieti D., Forus A., Myklebost O., Ectopic sequences from truncated HMGIC in liposarcomas are derived from various amplified chromosomal regions Genes Chromosomes and Cancer 2001 31 3 264 273 (Pubitemid 32521757)
58. Mantovani F., Covaceuszach S., Rustighi A., Sgarra R., Heath C., Goodwin G. H., Manfioletti G., NF- B mediated transcriptional activation is enhanced by the architectural factor HMGI-C Nucleic Acids Research 1998 26 6 1433 1439 (Pubitemid 28291618)
59. Schwanbeck R., Manfioletti G., Winiewski J. R., Architecture of high mobility group protein I-C DNA complex and its perturbation upon phosphorylation by Cdc2 kinase The Journal of Biological Chemistry 2000 275 3 1793 1801 (Pubitemid 30060801)
60. Fedele M., Berlingieri M. T., Scala S., Chiariotti L., Viglietto G., Rippel V., Bullerdiek J., Santoro M., Fusco A., Truncated and chimeric HMGI-C genes induce neoplastic transformation of NIH3T3 murine fibroblasts Oncogene 1998 17 4 413 418 (Pubitemid 28395904)
61. Berner J.-M., Meza-Zepeda L. A., Kools P. F. J., Forus A., Schoenmakers E. F. P. M., Van De Ven W. J. M., Fodstad., Myklebost O., HMGIC, the gene for an architectural transcription factor, is amplified and rearranged in a subset of human sarcomas Oncogene 1997 14 24 2935 2941 (Pubitemid 27315662)
62. Gamberi G., Ragazzini P., Benassi M. S., Ferrari C., Sollazzo M. R., Molendini L., Merli M., Magagnoli G., Ruggieri P., Balladelli A., Orlando C., Bacchini P., Pazzagli M., Picci P., Analysis of 12q13-15 genes in parosteal osteosarcoma Clinical Orthopaedics and Related Research 2000 377 195 204 (Pubitemid 30614885)
63. Meltzer P. S., Jankowski S. A., Dal Cin P., Sandberg A. A., Paz I. B., Coccia M. A., Identification and cloning of a novel amplified DNA sequence in human malignant fibrous histiocytoma derived from a region of chromosome 12 frequently rearranged in soft tissue tumors Cell Growth 1991 2 10 495 501
64. Florenes V. A., Moelandsmo G. M., Forus A., Andreassen A., Myklebost O., Fodstad O., MDM2 gene amplification and transcript levels in human sarcomas: relationship to TP53 gene status Journal of the National Cancer Institute 1994 86 17 1297 1302 (Pubitemid 24276791)
65. Noble-Topham S. E., Burrow S. R., Eppert K., Kandel R. A., Meltzer P. S., Bell R. S., Andrulis I. L., SAS is amplified predominantly in surface osteosarcoma Journal of Orthopaedic Research 1996 14 5 700 705 (Pubitemid 26376512)
66. Forus A., Florenes V. A., Maelandsmo G. M., Meltzer P. S., Fodstad O., Myklebost O., Mapping of amplification units in the q13-14 region of chromosome-12 in human sarcomassome amplica do not include MDM2 Cell Growth and Differentiation 1993 4 12 1065 1070 (Pubitemid 2020828)
67. Meza-Zepeda L. A., Forus A., Lygren B., Dahlberg A. B., Godager L. H., South A. P., Marenholz I., Lioumi M., Flrenes V. A., Mlandsmo G. M., Serra M., Mischke D., Nizetic D., Ragoussis J., Tarkkanen M., Nesland J. M., Knuutila S., Myklebost O., Positional cloning identifies a novel cyclophilin as a candidate amplified oncogene in 1q21 Oncogene 2002 21 14 2261 2269 (Pubitemid 34311380)
68. Nilsson M., Meza-Zepeda L. A., Mertens F., Forus A., Myklebost O., Mandahl N., Amplification of chromosome 1 sequences in lipomatous tumors and other sarcomas International Journal of Cancer 2004 109 3 363 369 (Pubitemid 38252764)
69. Chibon F., Mariani O., Derr J., Malinge S., Coindre J.-M., Guillou L., Lagac R., Aurias A., A subgroup of malignant fibrous histiocytomas is associated with genetic changes similar to those of well-differentiated liposarcomas Cancer Genetics and Cytogenetics 2002 139 1 24 29 (Pubitemid 36120402)
70. Vallone D., Battista S., Pierantoni G. M., Fedele M., Casalino L., Santoro M., Viglietto G., Fusco A., Verde P., Neoplastic transformation of rat thyroid cells requires the junB and fra-1 gene induction which is dependent on the HMGI-C gene product The EMBO Journal 1997 16 17 5310 5321 (Pubitemid 27380139)
71. Coindre J.-M., Pdeutour F., Aurias A., Well-differentiated and dedifferentiated liposarcomas Virchows Archiv 2010 456 2 167 179
72. Chibon F., Mariani O., Derr J., Mairal A., Coindre J.-M., Guillou L., Sastre X., Pdeutour F., Aurias A., ASK1 (MAP3K5) as a potential therapeutic target in malignant fibrous histiocytomas with 12q14q-q15 and 6q23 amplifications Genes Chromosomes and Cancer 2004 40 1 32 37 (Pubitemid 38524616)
73. Fletcher C. K. U., Krishnan K., Mertens F., Pathology and Genetics of Tumours of Soft Tissue and Bone 2002 Lyon, France IARC Press
74. Schwab J. H., Boland P., Guo T., Brennan M. F., Singer S., Healey J. H., Antonescu C. R., Skeletal metastases in myxoid liposarcoma: an unusual pattern of distant spread Annals of Surgical Oncology 2007 14 4 1507 1514 (Pubitemid 46536828)
75. Sheah K., Ouellette H. A., Torriani M., Nielsen G. P., Kattapuram S., Bredella M. A., Metastatic myxoid liposarcomas: imaging and histopathologic findings Skeletal Radiology 2008 37 3 251 258
76. ten Heuvel S. E., Hoekstra H. J., Van Ginkel R. J., Bastiaannet E., Suurmeijer A. J. H., Clinicopathologic prognostic factors in myxoid liposarcoma: a retrospective study of 49 patients with long-term follow-up Annals of Surgical Oncology 2007 14 1 222 229 (Pubitemid 44954293)
77. Canter R. J., Qin L.-X., Ferrone C. R., Maki R. G., Singer S., Brennan M. F., Why do patients with low-grade soft tissue sarcoma die? Annals of Surgical Oncology 2008 15 12 3550 3560
78. Chung P. W. M., Deheshi B. M., Ferguson P. C., Wunder J. S., Griffin A. M., Catton C. N., Bell R. S., White L. M., Kandel R. A., O'Sullivan B., Radiosensitivity translates into excellent local control in extremity myxoid liposarcoma: a comparison with other soft tissue sarcomas Cancer 2009 115 14 3254 3261
79. Antonescu C. R., Tschernyavsky S. J., Decuseara R., Leung D. H., Woodruff J. M., Brennan M. F., Bridge J. A., Neff J. R., Goldblum J. R., Ladanyi M., Prognostic impact of P53 status, TLS-CHOP fusion transcript structure, and histological grade in myxoid liposarcoma: a molecular and clinicopathologic study of 82 cases Clinical Cancer Research 2001 7 12 3977 3987 (Pubitemid 34044616)
80. Crozat A., Aman P., Mandahl N., Ron D., Fusion of CHOP to a novel RNA-binding protein in human myxoid liposarcoma Nature 1993 363 6430 640 644 (Pubitemid 23227627)
81. Panagopoulos I., Hglund M., Mertens F., Mandahl N., Mitelman F., man P., Fusion of the EWS and CHOP genes in myxoid liposarcoma Oncogene 1996 12 3 489 494 (Pubitemid 26059642)
82. Dal Cin P., Sciot R., Panagopoulos I., man P., Samson I., Mandahl N., Mitelman F., Van Den Berghe H., Fletcher C. D. M., Additional evidence of a variant translocation t(12;22) with EWS/CHOP fusion in myxoid liposarcoma: clinicopathological features Journal of Pathology 1997 182 4 437 441 (Pubitemid 27317209)
83. Sreekantaiah C., Karakousis C. P., Leong S. P. L., Sandberg A. A., Trisomy 8 as a nonrandom secondary change in myxoid liposarcoma Cancer Genetics and Cytogenetics 1991 51 2 195 205
84. Thelin-Jrnum S., Lassen C., Panagopoulos I., Mandahl N., man P., Identification of genes differentially expressed in TLS-CHOP carrying myxoid liposarcomas International Journal of Cancer 1999 83 1 30 33 (Pubitemid 29409472)
85. Cheng H., Dodge J., Mehl E., Liu S., Poulin N., van de Rijn M., Nielsen T. O., Validation of immature adipogenic status and identification of prognostic biomarkers in myxoid liposarcoma using tissue microarrays Human Pathology 2009 40 9 1244 1251
86. Tao Y., Pinzi V., Bourhis J., Deutsch E., Mechanisms of disease: signaling of the insulin-like growth factor 1 receptor pathwaytherapeutic perspectives in cancer Nature Clinical Practice Oncology 2007 4 10 591 602 (Pubitemid 47534758)
87. Bode-Lesniewska B., Frigerio S., Exner U., Abdou M. T., Moch H., Zimmermann D. R., Relevance of translocation type in myxoid liposarcoma and identification of a novel EWSR1-DDIT3 fusion Genes Chromosomes and Cancer 2007 46 11 961 971 (Pubitemid 47502836)
88. Forni C., Minuzzo M., Virdis E., Tamborini E., Simone M., Tavecchio M., Erba E., Grosso F., Gronchi A., Aman P., Casali P., D'Incalci M., Pilotti S., Mantovani R., Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors Molecular Cancer Therapeutics 2009 8 2 449 457
89. Grosso F., Jones R. L., Demetri G. D., Judson I. R., Blay J.-Y., Le Cesne A., Sanfilippo R., Casieri P., Collini P., Dileo P., Spreafico C., Stacchiotti S., Tamborini E., Tercero J. C., Jimeno J., D'Incalci M., Gronchi A., Fletcher J. A., Pilotti S., Casali P. G., Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study Lancet Oncology 2007 8 7 595 602 (Pubitemid 46995623)
90. Frapolli R., Tamborini E., Virdis E., Novel models of Myxoid Liposarcoma Xenografts mimicking the biological and pharmacological features of human tumors Clinical Cancer Research 2010 16 20 4958 4967
91. Bertolotti A., Lutz Y., Heard D. J., Chambon P., Tora L., hTAF(II)68, a novel RNA/ssDNA-binding protein with homology to the pro-oncoproteins TLS/FUS and EWS is associated with both TFIID and RNA polymerase II The EMBO Journal 1996 15 18 5022 5031 (Pubitemid 26315812)
92. Stolow D. T., Haynes S. R., Cabeza, a Drosophila gene encoding a novel RNA binding protein, shares homology with EWS and TLS, two genes involved in human sarcoma formation Nucleic Acids Research 1995 23 5 835 843
93. Morohoshi F., Arai K., Takahashi E.-I., Tanigami A., Ohki M., Cloning and mapping of a human RBP56 gene encoding a putative RNA binding protein similar to FUS/TLS and EWS proteins Genomics 1996 38 1 51 57 (Pubitemid 26423913)
94. Morohoshi F., Ootsuka Y., Arai K., Ichikawa H., Mitani S., Munakata N., Ohki M., Genomic structure of the human RBP56/hTAF(II)68 and FUS/TLS genes Gene 1998 221 2 191 198 (Pubitemid 29023746)
95. Andersson M. K., Sthlberg A., Arvidsson Y., Olofsson A., Semb H., Stenman G., Nilsson O., man P., The multifunctional FUS, EWS and TAF15 proto-oncoproteins show cell type-specific expression patterns and involvement in cell spreading and stress response BMC Cell Biology 2008 9, article 37
96. Zinszner H., Immanuel D., Yin Y., Liang F.-X., Ron D., A topogenic role for the oncogenic N-terminus of TLS: nucleolar localization when transcription is inhibited Oncogene 1997 14 4 451 461 (Pubitemid 27087108)
97. Zinszner H., Sok J., Immanuel D., Yin Y., Ron D., TLS (FUS) binds RNA in vivo and engages in nucleo-cytoplasmic shuttling Journal of Cell Science 1997 110 15 1741 1750 (Pubitemid 27352853)
98. Belyanskaya L. L., Gehrig P. M., Gehring H., Exposure on cell surface and extensive arginine methylation of ewing sarcoma (EWS) Protein The Journal of Biological Chemistry 2001 276 22 18681 18687
99. Tan A. Y., Manley J. L., TLS inhibits RNA polymerase III transcription Molecular and Cellular Biology 2010 30 1 186 196
100. Wang X., Arai S., Song X., Reichart D., Du K., Pascual G., Tempst P., Rosenfeld M. G., Glass C. K., Kurokawa R., Induced ncRNAs allosterically modify RNA-binding proteins in cis to inhibit transcription Nature 2008 454 7200 126 130 (Pubitemid 351934270)
101. Gardiner M., Toth R., Vandermoere F., Morrice N. A., Rouse J., Identification and characterization of FUS/TLS as a new target of ATM Biochemical Journal 2008 415 2 297 307
102. Wang X.-Z., Lawson B., Brewer J. W., Zinszner H., Sanjay A., Mi L.-J., Boorstein R., Kreibich G., Hendershot L. M., Ron D., Signals from the stressed endoplasmic reticulum induce C/EBP-homologous protein (CHOP/GADD153) Molecular and Cellular Biology 1996 16 8 4273 4280 (Pubitemid 26251229)
103. Batchvarova N., Wang X.-Z., Ron D., Inhibition of adipogenesis by the stress-induced protein CHOP (Gadd153) The EMBO Journal 1995 14 19 4654 4661
104. Cao Z., Umek R. M., McKnight S. L., Regulated expression of three C/EBP isoforms during adipose conversion of 3T3-L1 cells Genes and Development 1991 5 9 1538 1552 (Pubitemid 21906060)
105. Zinszner H., Albalat R., Ron D., A novel effector domain from the RNA-binding protein TLS or EWS is required for oncogenic transformation by CHOP Genes and Development 1994 8 21 2513 2526 (Pubitemid 24347243)
106. Kuroda M., Ishida T., Takanashi M., Satoh M., Machinami R., Watanabe T., Oncogenic transformation and inhibition of adipocytic conversion of preadipocytes by TLS/FUS-CHOP type II chimeric protein American Journal of Pathology 1997 151 3 735 744 (Pubitemid 27385605)
107. Prez-Mancera P. A., Vicente-Dueas C., Gonzlez-Herrero I., Snchez-Martn M., Flores-Corral T., Snchez-Garca I., Fat-specific FUS-DDIT3-transgenic mice establish PPAR inactivation is required to liposarcoma development Carcinogenesis 2007 28 10 2069 2073 (Pubitemid 47543364)
108. Cheng H., Dodge J., Mehl E., Liu S., Poulin N., van de Rijn M., Nielsen T. O., Validation of immature adipogenic status and identification of prognostic biomarkers in myxoid liposarcoma using tissue microarrays Human Pathology 2009 40 9 1244 1251
109. Prez-Losada J., Pintado B., Gutirrez-Adn A., Flores T., Baares-Gonzlez B., Del Campo J. C., Martn-Martn J. F., Battaner E., Snchez-Garca I., The chimeric FUS/TLS-CHOP fusion protein specifically induces liposarcomas in transgenic mice Oncogene 2000 19 20 2413 2422 (Pubitemid 30323474)
110. Negri T., Virdis E., Brich S., Bozzi F., Tamborini E., Tarantino E., Jocoll G., Cassinelli G., Grosso F., Sanfilippo R., Casalini P., Greco A., Pierotti M. A., Pilotti S., Functional mapping of receptor tyrosine kinases in myxoid liposarcoma Clinical Cancer Research 2010 16 14 3581 3593
111. Riggi N., Cironi L., Provero P., Suv M.-L., Stehle J.-C., Baumer K., Guillou L., Stamenkovic I., Expression of the FUS-CHOP fusion protein in primary mesenchymal progenitor cells gives rise to a model of myxoid liposarcoma Cancer Research 2006 66 14 7016 7023 (Pubitemid 44197677)
112. Engstrm K., Willn H., Kbjrn-Gustafsson C., Andersson C., Olsson M., Gransson M., Jrnum S., Olofsson A., Warnhammar E., man P., The myxoid/round cell liposarcoma fusion oncogene FUS-DDIT3 and the normal DDIT3 induce a liposarcoma phenotype in transfected human fibrosarcoma cells American Journal of Pathology 2006 168 5 1642 1653
113. Andersson M. K., Gransson M., Olofsson A., Andersson C., man P., Nuclear expression of FLT1 and its ligand PGF in FUS-DDIT3 carrying myxoid liposarcomas suggests the existence of an intracrine signaling loop BMC Cancer 2010 10, article 249
114. Samuels Y., Wang Z., Bardelli A., Silliman N., Ptak J., Szabo S., Yan H., Gazdar A., Powell S. M., Riggins G. J., Willson J. K. V., Markowitz S., Kinzler K. W., Vogelstein B., Velculescu V. E., High frequency of mutations of the PIK3CA gene in human cancers Science 2004 304 5670, article 554
115. Thomas R. K., Baker A. C., DeBiasi R. M., Winckler W., LaFramboise T., Lin W. M., Wang M., Feng W., Zander T., MacConnaill L. E., Lee J. C., Nicoletti R., Hatton C., Goyette M., Girard L., Majmudar K., Ziaugra L., Wong K.-K., Gabriel S., Beroukhim R., Peyton M., Barretina J., Dutt A., Emery C., Greulich H., Shah K., Sasaki H., Gazdar A., Minna J., Armstrong S. A., Mellinghoff I. K., Hodi F. S., Dranoff G., Mischel P. S., Cloughesy T. F., Nelson S. F., Liau L. M., Mertz K., Rubin M. A., Moch H., Loda M., Catalona W., Fletcher J., Signoretti S., Kaye F., Anderson K. C., Demetri G. D., Dummer R., Wagner S., Herlyn M., Sellers W. R., Meyerson M., Garraway L. A., High-throughput oncogene mutation profiling in human cancer Nature Genetics 2007 39 3 347 351 (Pubitemid 46328493)
116. Barretina J., Taylor B. S., Banerji S., Ramos A. H., Lagos-Quintana M., Decarolis P. L., Shah K., Socci N. D., Weir B. A., Ho A., Chiang D. Y., Reva B., Mermel C. H., Getz G., Antipin Y., Beroukhim R., Major J. E., Hatton C., Nicoletti R., Hanna M., Sharpe T., Fennell T. J., Cibulskis K., Onofrio R. C., Saito T., Shukla N., Lau C., Nelander S., Silver S. J., Sougnez C., Viale A., Winckler W., Maki R. G., Garraway L. A., Lash A., Greulich H., Root D. E., Sellers W. R., Schwartz G. K., Antonescu C. R., Lander E. S., Varmus H. E., Ladanyi M., Sander C., Meyerson M., Singer S., Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy Nature Genetics 2010 42 8 715 721
117. Cantley L. C., The phosphoinositide 3-kinase pathway Science 2002 296 5573 1655 1657 (Pubitemid 34579158)
118. Guillou L., Wadden C., Coindre J.-M., Krausz T., Fletcher C. D. M., 'Proximal-type' epithelioid sarcoma, a distinctive aggressive neoplasm showing rhabdoid features: clinicopathologic, immunohistochemical, and ultrastructural study of a series American Journal of Surgical Pathology 1997 21 2 130 146 (Pubitemid 27084052)
119. Miettinen M., Enzinger F. M., Epithelioid variant of pleomorphic liposarcoma: a study of 12 cases of a distinctive variant of high-grade liposarcoma Modern Pathology 1999 12 7 722 728 (Pubitemid 29354886)
120. Downes K. A., Goldblum J. R., Montgomery E. A., Fisher C., Pleomorphic liposarcoma: a clinicopathologic analysis of 19 cases Modern Pathology 2001 14 3 179 184 (Pubitemid 32246821)
121. Stewart M. G., Schwartz M. R., Alford B. R., Atypical and malignant lipomatous lesions of the head and neck Archives of OtolaryngologyHead and Neck Surgery 1994 120 10 1151 1155 (Pubitemid 24313271)
122. Allen P. W., Strungs I., MacCormac L. B., Atypical subcutaneous fatty tumors: a review of 37 referred cases Pathology 1998 30 2 123 135 (Pubitemid 28211782)
123. Taylor B. S., Barretina J., Socci N. D., DeCarolis P., Ladanyi M., Meyerson M., Singer S., Sander C., Functional copy-number alterations in cancer PLoS ONE 2008 3 9
124. Idbaih A., Coindre J.-M., Derr J., Mariani O., Terrier P., Ranchre D., Mairal A., Aurias A., Myxoid malignant fibrous histiocytoma and pleomorphic liposarcoma share very similar genomic imbalances Laboratory Investigation 2005 85 2 176 181 (Pubitemid 40208921)
125. Schmidt H., Bartel F., Kappler M., Wrl P., Lange H., Bache M., Holzhausen H.-J., Taubert H., Gains of 13q are correlated with a poor prognosis in liposarcoma Modern Pathology 2005 18 5 638 644 (Pubitemid 40676374)
126. Singer S., Socci N. D., Ambrosini G., Sambol E., Decarolis P., Wu Y., O'Connor R., Maki R., Viale A., Sander C., Schwartz G. K., Antonescu C. R., Gene expression profiling of liposarcoma identifies distinct biological types/subtypes and potential therapeutic targets in well-differentiated and dedifferentiated liposarcoma Cancer Research 2007 67 14 6626 6636 (Pubitemid 47105508)
127. Dotiwala F., Harrison J. C., Jain S., Sugawara N., Haber J. E., Mad2 prolongs DNA damage checkpoint arrest caused by a double-strand break via a centromere-dependent mechanism Current Biology 2010 20 4 328 332
128. Vassilev L. T., Vu B. T., Graves B., Carvajal D., Podlaski F., Filipovic Z., Kong N., Kammlott U., Lukacs C., Klein C., Fotouhi N., Liu E. A., In vivo activation of the p53 pathway by small-molecule antagonists of MDM2 Science 2004 303 5659 844 848 (Pubitemid 38174664)
129. Shangary S., Qin D., McEachern D., Liu M., Miller R. S., Qiu S., Nikolovska-Coleska Z., Ding K., Wang G., Chen J., Bernard D., Zhang J., Lu Y., Gu Q., Shah R. B., Pienta K. J., Ling X., Kang S., Guo M., Sun Y., Yang D., Wang S., Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition Proceedings of the National Academy of Sciences of the United States of America 2008 105 10 3933 3938 (Pubitemid 351723502)
130. Ding K., Lu Y., Nikolovska-Coleska Z., Wang G., Qiu S., Shangary S., Gao W., Qin D., Stuckey J., Krajewski K., Roller P. P., Wang S., Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2-p53 interaction Journal of Medicinal Chemistry 2006 49 12 3432 3435 (Pubitemid 43902447)
131. Shangary S., Wang S., Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy Annual Review of Pharmacology and Toxicology 2009 49 223 241
132. Ringshausen I., O'Shea C. C., Finch A. J., Swigart L. B., Evan G. I., Mdm2 is critically and continuously required to suppress lethal p53 activity in vivo Cancer Cell 2006 10 6 501 514 (Pubitemid 44854749)
133. Tovar C., Rosinski J., Filipovic Z., Higgins B., Kolinsky K., Hilton H., Zhao X., Vu B. T., Qing W., Packman K., Myklebost O., Heimbrook D. C., Vassilev L. T., Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy Proceedings of the National Academy of Sciences of the United States of America 2006 103 6 1888 1893 (Pubitemid 43228788)
134. Dickens M. P., Fitzgerald R., Fischer P. M., Small-molecule inhibitors of MDM2 as new anticancer therapeutics Seminars in Cancer Biology 2009 20 1 10 18
135. Arts J. P. M., Valckx A., Blattner C., JNJ-26854165- a novel hdm2 antagonist in clinical development showing broad-spectrum pre-clinical anti-tumour activity against solid malignancies Proceedings of the American Association for Cancer Research 2008 49. abstract no. 1592
136. Pipeline R. P.,. 2008 (http://www.ascenta.com/)
137. ClinicalTrials.govRO5045337, 2010, http://clinicaltrials.gov/ct2/results? term=RO5045337
138. Chen Y.-N. P., Sharma S. K., Ramsey T. M., Jiang L., Martin M. S., Baker K., Adams P. D., Bair K. W., Kaelin W. G. Jr., Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists Proceedings of the National Academy of Sciences of the United States of America 1999 96 8 4325 4329 (Pubitemid 29190335)
139. Shapiro G. I., Cyclin-dependent kinase pathways as targets for cancer treatment Journal of Clinical Oncology 2006 24 11 1770 1783 (Pubitemid 46628473)
140. De Azevedo W. F., Leclerc S., Meijer L., Havlicek L., Strnad M., Kim S.-H., Inhibition of cyclin-dependent kinases by purine analogues. Crystal structure of human cdk2 complexed with roscovitine European Journal of Biochemistry 1997 243 1-2 518 526 (Pubitemid 27060442)
141. Shapiro G. I., Preclinical and clinical development of the cyclin-dependent kinase inhibitor flavopiridol Clinical Cancer Research 2004 10 12 4270s 4275s (Pubitemid 38812461)
142. Sedlacek H. H., Mechanisms of action of flavopiridol Critical Reviews in Oncology/Hematology 2001 38 2 139 170 (Pubitemid 32328317)
143. Matranga C. B., Shapiro G. I., Selective sensitization of transformed cells to flavopiridol-induced apoptosis following recruitment to S-phase Cancer Research 2002 62 6 1707 1717 (Pubitemid 34408493)
144. Bible K. C., Kaufmann S. H., Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: the importance of sequence of administration Cancer Research 1997 57 16 3375 3380 (Pubitemid 27355478)
145. Jung C. P., Motwani M. V., Schwartz G. K., Flavopiridol increases sensitization to gemcitabine in human gastrointestinal cancer cell lines and correlates with down-regulation of ribonucleotide reductase M2 subunit Clinical Cancer Research 2001 7 8 2527 2536 (Pubitemid 32751659)
146. Lapenna S., Giordano A., Cell cycle kinases as therapeutic targets for cancer Nature Reviews Drug Discovery 2009 8 7 547 566
147. Benson C., White J., De Bono J., O'Donnell A., Raynaud F., Cruickshank C., McGrath H., Walton M., Workman P., Kaye S., Cassidy J., Gianella-Borradori A., Judson I., Twelves C., A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days British Journal of Cancer 2007 96 1 29 37 (Pubitemid 46094635)
148. Fry D. W., Harvey P. J., Keller P. R., Elliott W. L., Meade M. A., Trachet E., Albassam M., Zheng X., Leopold W. R., Pryer N. K., Toogood P. L., Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts Molecular Cancer Therapeutics 2004 3 11 1427 1437 (Pubitemid 39562588)
149. Demetri G. D., Fletcher C. D. M., Mueller E., Sarraf P., Naujoks R., Campbell N., Spiegelman B. M., Singer S., Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor- ligand troglitazone in patients with liposarcoma Proceedings of the National Academy of Sciences of the United States of America 1999 96 7 3951 3956 (Pubitemid 29169017)
150. Tontonoz P., Hu E., Graves R. A., Budavari A. I., Spiegelman B. M., mPPAR 2: tissue-specific regulator of an adipocyte enhancer Genes and Development 1994 8 10 1224 1234
151. Sears I. B., MacGinnitie M. A., Kovacs L. G., Graves R. A., Differentiation-dependent expression of the brown adipocyte uncoupling protein gene: regulation by peroxisome proliferator-activated receptor Molecular and Cellular Biology 1996 16 7 3410 3419 (Pubitemid 26199860)
152. Debrock G., Vanhentenrijk V., Sciot R., Debiec-Rychter M., Oyen R., Van Oosterom A., A phase II trial with rosiglitazone in liposarcoma patients British Journal of Cancer 2003 89 8 1409 1412 (Pubitemid 37386592)
153. Takebayashi Y., Pourquier P., Yoshida A., Kohlhagen G., Pommier Y., Poisoning of human DNA topoisomerase I by ecteinascidin 743, an anticancer drug that selectively alkylates DNA in the minor groove Proceedings of the National Academy of Sciences of the United States of America 1999 96 13 7196 7201 (Pubitemid 29299638)
154. Fayette J., Boyle H., Chabaud S., Favier B., Engel C., Cassier P., Thiesse P., Meus P., Sunyach M.-P., Vaz G., Ray-Coquard I., Ranchre D., Decouvelaere A.-V., Alberti L., Prol D., Blay J.-Y., Efficacy of trabectedin for advanced sarcomas in clinical trials versus compassionate use programs: analysis of 92 patients treated in a single institution Anti-Cancer Drugs 2010 21 1 113 119
155. Thornton K. A., Trabectedin: the evidence for its place in therapy in the treatment of soft tissue sarcoma Core Evidence 2010 4 191 198
156. Pommier Y., Kohlhagen G., Bailly C., Waring M., Mazumder A., Kohn K. W., DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the caribbean tunicate Ecteinascidia turbinata Biochemistry 1996 35 41 13303 13309 (Pubitemid 26349423)
157. Friedman D., Hu Z., Kolb E. A., Gorfajn B., Scotto K. W., Ecteinascidin-743 inhibits activated but not constitutive transcription Cancer Research 2002 62 12 3377 3381 (Pubitemid 34651382)
158. Minuzzo M., Marchini S., Broggini M., Faircloth G., D'Incalci M., Mantovani R., Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743 Proceedings of the National Academy of Sciences of the United States of America 2000 97 12 6780 6784 (Pubitemid 30412791)
159. Takebayashi Y., Pourquier P., Zimonjic D. B., Nakayama K., Emmert S., Ueda T., Urasaki Y., Kanzaki A., Akiyama S.-I., Popescu N., Kraemer K. H., Pommier Y., Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair Nature Medicine 2001 7 8 961 966 (Pubitemid 32756435)
160. Guirouilh-Barbat J., Redon C., Pommier Y., Transcription-coupled DNA double-strand breaks are mediated via the nucleotide excision repair and the Mre11-Rad50-Nbs1 complex Molecular Biology of the Cell 2008 19 9 3969 3981
161. Soares D. G., Escargueil A. E., Poindessous V., Sarasin A., De Gramont A., Bonatto D., Henriques J. A. P., Larsen A. K., Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743 Proceedings of the National Academy of Sciences of the United States of America 2007 104 32 13062 13067 (Pubitemid 351737593)
162. Tavecchio M., Simone M., Erba E., Chiolo I., Liberi G., Foiani M., D'Incalci M., Damia G., Role of homologous recombination in trabectedin-induced DNA damage European Journal of Cancer 2008 44 4 609 618
163. Gransson M., Elias E., Sthlberg A., Olofsson A., Andersson C., man P., Myxoid liposarcoma FUS-DDIT3 fusion oncogene induces C/EBP -mediated interleukin 6 expression International Journal of Cancer 2005 115 4 556 560 (Pubitemid 40656712)
164. Gransson M., Andersson M. K., Forni C., Sthlberg A., Andersson C., Olofsson A., Mantovani R., man P., The myxoid liposarcoma FUS-DDIT3 fusion oncoprotein deregulates NF- B target genes by interaction with NFKBIZ Oncogene 2009 28 2 270 278
165. Germano G., Frapolli R., Simone M., Tavecchio M., Erba E., Pesce S., Pasqualini F., Grosso F., Sanfilippo R., Casali P. G., Gronchi A., Virdis E., Tarantino E., Pilotti S., Greco A., Nebuloni M., Galmarini C. M., Tercero J. C., Mantovani A., D'Incalci M., Allavena P., Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells Cancer Research 2010 70 6 2235 2244
166. Workman P., Clarke P. A., Raynaud F. I., Van Montfort R. L.M., Drugging the PI3 kinome: from chemical tools to drugs in the clinic Cancer Research 2010 70 6 2146 2157
167. Folkes A. J., Ahmadi K., Alderton W. K., Alix S., Baker S. J., Box G., Chuckowree I. S., Clarke P. A., Depledge P., Eccles S. A., Friedman L. S., Hayes A., Hancox T. C., Kugendradas A., Lensun L., Moore P., Olivero A. G., Pang J., Patel S., Pergl-Wilson G. H., Raynaud F. I., Robson A., Saghir N., Salphati L., Sohal S., Ultsch M. H., Valenti M., Wallweber H. J. A., Nan C. W., Wiesmann C., Workman P., Zhyvoloup A., Zvelebil M. J., Shuttleworth S. J., The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin- 4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer Journal of Medicinal Chemistry 2008 51 18 5522 5532
168. Raynaud F. I., Eccles S. A., Patel S., Alix S., Box G., Chuckowree I., Folkes A., Gowan S., Brandon A. D. H., Di Stefano F., Hayes A., Henley A. T., Lensun L., Pergl-Wilson G., Robson A., Saghir N., Zhyvoloup A., McDonald E., Sheldrake P., Shuttleworth S., Valenti M., Nan C. W., Clarke P. A., Workman P., Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941 Molecular Cancer Therapeutics 2009 8 7 1725 1738
169. Ihle N. T., Lemos R. Jr., Wipf P., Yacoub A., Mitchell C., Siwak D., Mills G. B., Dent P., Kirkpatrick D. L., Powis G., Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic ras is a dominant predictor for resistance Cancer Research 2009 69 1 143 150
170. O'Brien C., Wallin J. J., Sampath D., GuhaThakurta D., Savage H., Punnoose E. A., Guan J., Berry L., Prior W. W., Amler L. C., Belvin M., Friedman L. S., Lackner M. R., Predictive biomarkers of sensitivity to the phosphatidylinositol 3′ kinase inhibitor GDC-0941 in breast cancer preclinical models Clinical Cancer Research 2010 16 14 3670 3683
171. Di Nicolantonio F., Arena S., Tabernero J., Grosso S., Molinari F., Macarulla T., Russo M., Cancelliere C., Zecchin D., Mazzucchelli L., Sasazuki T., Shirasawa S., Geuna M., Frattini M., Baselga J., Gallicchio M., Biffo S., Bardelli A., Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus The Journal of Clinical Investigation 2010 120 8 2858 2866
172. Cecchi F., Rabe D. C., Bottaro D. P., Targeting the HGF/Met signalling pathway in cancer European Journal of Cancer 2010 46 7 1260 1270
173. Eder J. P., Shapiro G. I., Appleman L. J., Zhu A. X., Miles D., Keer H., Cancilla B., Chu F., Hitchcock-Bryan S., Sherman L., McCallum S., Heath E. I., Boerner S. A., LoRusso P. M., A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2 Clinical Cancer Research 2010 16 13 3507 3516
174. Joensuu H., Fletcher C., Dimitrijevic S., Silberman S., Roberts P., Demetri G., Management of malignant gastrointestinal stromal tumours Lancet Oncology 2002 3 11 655 664 (Pubitemid 35314908